Items where authors include "Behrens, F"

Article

Kaeley, GS, Schett, G, Conaghan, PG orcid.org/0000-0002-3478-5665 et al. (6 more authors) (2023) Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study. Rheumatology. ISSN 1462-0324

Coates, LC, Tillett, W, D'Agostino, MA et al. (8 more authors) (2022) Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. The Lancet Rheumatology, 4 (4). e262-e273. ISSN 2665-9913

Mease, PJ, Smolen, JS, Behrens, F et al. (11 more authors) (2020) A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Annals of the Rheumatic Diseases, 79 (1). pp. 123-131. ISSN 0003-4967

Gossec, L, McGonagle, D, Korotaeva, T et al. (4 more authors) (2018) Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. The Journal of Rheumatology, 45 (1). pp. 6-13. ISSN 0315-162X

Bowes, J, Loehr, S, Budu-Aggrey, A et al. (21 more authors) (2015) PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases, 74 (10). pp. 1882-1885. ISSN 0003-4967

Bowes, J, Budu-Aggrey, A, Huffmeier, U et al. (29 more authors) (2015) Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 6. 7741.

Bowes, J, Budu-Aggrey, A, Huffmeier, U et al. (29 more authors) (2015) Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 6. 6046. ISSN 2041-1723

Conference or Workshop Item

Behrens, F, Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Behrens, F, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Studies. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Behrens, F, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase-3, Randomized, Placebo-Controlled Studies. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.